Registration Dossier

Diss Factsheets

Toxicological information

Neurotoxicity

Currently viewing:

Administrative data

Endpoint:
neurotoxicity
Adequacy of study:
supporting study
Reliability:
1 (reliable without restriction)
Rationale for reliability incl. deficiencies:
other: GLP guideline study
Cross-reference
Reason / purpose for cross-reference:
reference to same study

Data source

Reference
Reference Type:
study report
Title:
Unnamed
Year:
2002
Report date:
2002

Materials and methods

Principles of method if other than guideline:
other: OECD 408
GLP compliance:
yes

Test material

Constituent 1
Chemical structure
Reference substance name:
Imidazole
EC Number:
206-019-2
EC Name:
Imidazole
Cas Number:
288-32-4
Molecular formula:
C3H4N2
IUPAC Name:
1H-imidazole
Details on test material:
Imidazole (CAS: 288-32-4), purity 99.8%

Test animals

Species:
rat
Strain:
Wistar
Sex:
male/female

Administration / exposure

Route of administration:
other: gavage
Vehicle:
water
Duration of treatment / exposure:
Exposure period: 90 day(s)
Frequency of treatment:
7/wk
Doses / concentrations
Remarks:
Doses / Concentrations:
0, 20, 60, 180 mg/kg bw/d
Basis:

No. of animals per sex per dose:
100
Control animals:
yes, concurrent vehicle
Details on study design:
Type: other: 90 d-study
Observation period: none

Results and discussion

Any other information on results incl. tables

Result: negative
No behavioral changes were noted at any of the dose levels including 180 mg/kg bw/d during the numerous tests performed
in the functional observation battery, FOB, and the motor activity.

Applicant's summary and conclusion

Executive summary:

A 90 day oral study in Wistar rats treated ad dose levels from 20 to 180 mg/kg bw/day found no treatment related alterations in behavioural tests (Functional Observational Battery, FOB) or motor activity assessments. The gavage dose levels were 0 (vehicle control, water), 20, 60 or 180 mg/kg bw/day. In addition, the brain, spinal cord and peripheral nervous system were examined by histopathology (control group and top dose group), but no treatment-related findings were noted. The no observable effect level (NOAEL) was 180 mg/kg bw/d for these endpoints in this study.